Comprehensive Pharmacological Profiling of Ghrelin Receptor Ligands Reveals Key Differences Between Agonists, Antagonists, and Inverse Agonists
Using a novel label-free DMR assay alongside traditional calcium mobilization, researchers systematically characterized ghrelin receptor ligands including the endogenous peptides ghrelin, desacyl-ghrelin, and LEAP2, demonstrating that DMR can distinguish antagonists from inverse agonists — a distinction the calcium assay misses.
Quick Facts
What This Study Found
Ghrelin, anamorelin, HM01, and HM03 behaved as potent full GHSR agonists in both assays. LEAP2(1-14) was identified as a GHSR inverse agonist in DMR but not calcium assays. PF-05190457, HM04, and H1498 acted as inverse agonists in DMR but only antagonists in calcium mobilization, demonstrating DMR's superior ability to discriminate receptor pharmacology.
Key Numbers
Characterized multiple GHSR ligand types: agonists, antagonists, and inverse agonists using the DMR assay.
How They Did This
In vitro pharmacological characterization using CHO cells expressing human GHSR. Two parallel assays: label-free dynamic mass redistribution (DMR) and calcium mobilization. Tested endogenous peptides (ghrelin, desacyl-ghrelin, LEAP2) and synthetic ligands (anamorelin, HM01, HM03, HM04, YIL-781, PF-05190457, R011, H1498).
Why This Research Matters
Understanding the precise pharmacology of ghrelin receptor ligands is critical for developing drugs targeting appetite, cachexia, metabolic disorders, and addiction. This study provides the most comprehensive comparison of GHSR ligands to date and introduces a superior assay method for distinguishing different types of receptor modulation.
The Bigger Picture
The ghrelin system is a major therapeutic target — agonists like anamorelin treat cancer cachexia while inverse agonists are being explored for obesity and addiction. This systematic characterization helps researchers select the right tool compounds and understand the nuances of ghrelin receptor pharmacology.
What This Study Doesn't Tell Us
Entirely in vitro using a single cell line (CHO-GHSR). Pharmacological profiles in recombinant systems may not fully reflect in vivo receptor behavior. No functional outcome data (appetite, GH release) assessed. Patent literature compounds have limited published characterization.
Questions This Raises
- ?Does the distinction between GHSR antagonism and inverse agonism matter for clinical outcomes in patients?
- ?Could LEAP2-based peptides be developed as therapeutics given their inverse agonist profile?
- ?How do these pharmacological profiles translate to in vivo effects on appetite and metabolism?
Trust & Context
- Key Stat:
- 12 GHSR ligands profiled Most comprehensive pharmacological comparison of ghrelin receptor ligands to date, revealing that DMR assay detects inverse agonism missed by standard calcium assays
- Evidence Grade:
- Rated preliminary: in vitro pharmacological characterization only. Provides important tool compound data but no clinical or in vivo validation.
- Study Age:
- Published in 2024. Uses current pharmacological assay technology and includes recently developed compounds.
- Original Title:
- In vitro pharmacological characterization of growth hormone secretagogue receptor ligands using the dynamic mass redistribution and calcium mobilization assays.
- Published In:
- European journal of pharmacology, 981, 176880 (2024)
- Authors:
- Sturaro, Chiara(2), Ruzza, Chiara(2), Ferrari, Federica, Pola, Pietro, Argentieri, Michela, Frezza, Alessia, Marzola, Erika, Bettegazzi, Barbara, Cattaneo, Stefano, Pietra, Claudio, Malfacini, Davide, Calò, Girolamo
- Database ID:
- RPEP-09331
Evidence Hierarchy
Frequently Asked Questions
What is the ghrelin receptor and why is it important?
The ghrelin receptor (GHSR) is activated by the 'hunger hormone' ghrelin and controls appetite, growth hormone release, and metabolism. Drugs that activate it can treat severe weight loss (cachexia) in cancer patients, while drugs that block it may help with obesity and addiction.
What's the difference between a receptor antagonist and an inverse agonist?
An antagonist blocks a receptor so nothing can activate it, but doesn't change its baseline activity. An inverse agonist goes further — it actually reduces the receptor's baseline activity below normal. This distinction matters because the ghrelin receptor is naturally active even without ghrelin, so inverse agonists may have stronger therapeutic effects.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09331APA
Sturaro, Chiara; Ruzza, Chiara; Ferrari, Federica; Pola, Pietro; Argentieri, Michela; Frezza, Alessia; Marzola, Erika; Bettegazzi, Barbara; Cattaneo, Stefano; Pietra, Claudio; Malfacini, Davide; Calò, Girolamo. (2024). In vitro pharmacological characterization of growth hormone secretagogue receptor ligands using the dynamic mass redistribution and calcium mobilization assays.. European journal of pharmacology, 981, 176880. https://doi.org/10.1016/j.ejphar.2024.176880
MLA
Sturaro, Chiara, et al. "In vitro pharmacological characterization of growth hormone secretagogue receptor ligands using the dynamic mass redistribution and calcium mobilization assays.." European journal of pharmacology, 2024. https://doi.org/10.1016/j.ejphar.2024.176880
RethinkPeptides
RethinkPeptides Research Database. "In vitro pharmacological characterization of growth hormone ..." RPEP-09331. Retrieved from https://rethinkpeptides.com/research/sturaro-2024-in-vitro-pharmacological-characterization
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.